Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
US retinal specialists identify 4D Molecular Therapeutics’ 4D-150, Adverum Biotechnologies’ Ixo-vec, and Johnson & Johnson’s JNJ-1887 as most likely pipeline candidates for prescription if approved. Exton, PA., July 24, 2024 – The American Society of Retinal Specialists (ASRS) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking advancements in gene therapy for retinal disorders. […]
Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors
Ophthalmologists are cautious about prescribing the current geographic atrophy (GA) treatment options Syfovre and Izervay, introduced in 2023 as the first-ever therapy for GA, according to Spherix Global Insights. EXTON, PA., June 27, 2024 – Prior to 2023, there was no treatment for GA, a progressive form of dry age-related macular degeneration that results in […]
Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
New prescriptions for Vabysmo and Eylea HD outpace reported current brand share, indicating further growth of the brands, according to Spherix Global Insights. EXTON, PA., June 24, 2024 – The treatment landscape for Diabetic Macular Edema (DME) continues to evolve, with innovative therapies and emerging data significantly shaping prescribing patterns. DME is the leading cause […]
Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market
Pending trial results supporting prescribers’ efficacy and safety demands, gene therapies are poised to capture upwards of one-fifth of the AMD, GA and DME markets, according to Spherix Global Insights. EXTON, PA., May 1, 2024 — In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases, have become a leading focus […]
Regeneron and Genentech battle for ophthalmologists’ affinity in Eylea HD, Vabysmo matchup
After seven months on the market, Regeneron’s Eylea HD is already making strides with ophthalmologists. According to Spherix Global Insights’ research, 81% of ophthalmologists who use Eylea HD to treat wet age-related macular degeneration (AMD) are “highly satisfied,” which tracks closely to the 87% who say the same about Roche and Genentech’s Vabysmo, which has […]
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
Research conducted by Spherix Global Insights reveals Retinal Specialists likely to adopt gene therapies. Exton, PA., March 19, 2024 – Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising pathway for delivering genetic material with precision and […]
Stakes Are High for Regeneron’s Eylea HD as Genentech’s Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
Navigating the landscape of Wet AMD Therapies During AMD Awareness Month EXTON, PA., February 8, 2024 — As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD, the need for optimal treatment solutions becomes increasingly evident. Wet AMD poses a particularly severe threat to vision, necessitating […]
“I Need to See It With My Own Eyes”: How US Ophthalmologists React to Apellis’ Syfovre Safety Warnings When Managing Geographic Atrophy
Ophthalmologists’ reservations about using Syfovre in Geographic Atrophy are more limited to “new start” patients, according to Spherix Global Insights. [Exton PA, December 14, 2023] — Geographic Atrophy (GA), the most severe stage of dry age-related macular degeneration (dAMD), poses a significant challenge as retinal cells atrophy, resulting in irreversible lesions that impact central vision. […]
Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
Despite Vabysmo’s gains in 2023, Eylea HD will prove to be a formidable force in the coming year. [Exton PA, November 1, 2023] — As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has begun to evolve. Spherix Global Insights has unveiled its latest […]
First-to-Market Edge for Apellis’s Syfovre in Geographic Atrophy Diminished in the Face of an Unexpected Safety Signal
Prospects for Syfovre uptake and trust in Apellis take a plunge following reports of intraocular inflammation, according to Spherix Global Insights EXTON, Pa., July 28, 2023 – For many who have been following the retina market, the news about the emerging safety signal associated with Apellis’ Syfovre in geographic atrophy (GA) feels very similar to […]
